Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma
| Autor: | Kosuke Kaji, Masao Fujimoto, Yasuhide Ikenaka, Hitoshi Yoshiji, Masahito Uemura, Mitsuteru Kitade, Hideto Kawaratani, Hiroshi Fukui, Tatsuhiro Tsujimoto, Akira Mitoro, Masaharu Yamazaki, Motoyuki Yoshida, Masayoshi Sawai, Masahisa Toyohara, Ryuichi Noguchi, Junichi Yamao |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A medicine.medical_specialty Carcinoma Hepatocellular Angiotensin-Converting Enzyme Inhibitors Neovascularization chemistry.chemical_compound Internal medicine medicine Menatetrenone Perindopril Humans AFP-L3 Aged Neovascularization Pathologic Hepatology business.industry Liver Neoplasms Drug Synergism Vitamin K 2 Middle Aged medicine.disease Angiotensin II Survival Rate Vascular endothelial growth factor Endocrinology chemistry Hepatocellular carcinoma Catheter Ablation Cancer research Drug Therapy Combination Female Neoplasm Recurrence Local medicine.symptom Liver cancer business medicine.drug |
| Zdroj: | Journal of Hepatology. 51:315-321 |
| ISSN: | 0168-8278 |
| DOI: | 10.1016/j.jhep.2009.04.011 |
| Popis: | Background/Aims No chemopreventive agent has been approved against hepatocellular carcinoma (HCC) yet. Since neovascularization plays a pivotal role in HCC, an angiostatic agent is considered as one of the promising approaches. The aim of this study was to elucidate the combined effect of the clinically used vitamin K 2 (VK) and angiotensin-converting enzyme inhibitor (ACE-I) on cumulative recurrence after curative treatment on a total of 87 patients, especially in consideration of neovascularization. Methods VK (menatetrenone; 45mg/day) and/or ACE-I (perindopril; 4mg/day) were administered for 36–48 months after curative therapy for HCC. The cumulative recurrence and several indices were analyzed. Results A 48-month follow-up revealed that the combination treatment with VK and ACE-I markedly inhibited the cumulative recurrence of HCC in association with suppression of the serum level of the vascular endothelial growth factor (VEGF); a central angiogenic factor. The serum level of lectin-reactive α-fetoprotein was also suppressed almost in parallel with VEGF. These beneficial effects were not observed with single treatment using VK or ACE-I. Conclusions The combination treatment of VK and ACE-I may suppress the cumulative recurrence of HCC after the curative therapy, at least partly through suppression of the VEGF-mediated neovascularization. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect